It was proposed that insulin-degrading enzyme (IDE) participates in the clearance of amyloid A (AA) in the brain, and its low expression or activity may be relevant for the progression of Alzheimer disease. We performed a longitudinal study of brain level, activity, and distribution of IDE in transgenic mice (Tg2576) expressing the Swedish mutation in human AA precursor protein.
INTRODUCTION
One of the pathologic features of Alzheimer disease (AD) brain is the presence of senile plaques in the cerebral cortex composed of amyloid A (AA) peptide, dystrophic neurites, neurofibrillary tangles, and congophilic angiopathy (1) . In patients with sporadic AD, the accumulation of AA in the diseased brain is a complex and heterogeneous process (2) involving secretase activity (3), impaired clearance or deficient peptide catabolism, or both (4, 5) . In this context, proteolytic processing of AA deserves special attention because it is one of the major factors that modulates the levels of brain-soluble AA. A group of zincYmetalloendopeptidases, including Neprilysin, endothelin-converting enzymes, and insulin-degrading enzyme (IDE), may regulate the steady state levels of AA in the mammalian brain. The physiological role of these proteases in vivo has been recently confirmed with functional studies using genetic deletion strategies in mice ([6Y9], reviewed in [10] ). Moreover, transgenic overexpression of IDE and Neprilysin in a mouse model of AD showed a dramatic decrease in brain AA levels and prolonged lifespan (11, 12) . IDE, or insulysin (13) , is a ubiquitous metalloendopeptidase capable of degrading several peptides with a high propensity to form amyloid fibrils in vitro and in vivo. These include insulin, glucagon, amylin, atrial natriuretic peptide, calcitonin, AA ( [14] , reviewed in [15] ), and the ABri and ADan peptides associated with hereditary dementia (16) . IDE knockout mice showed accumulation of the carboxyl terminal intracellular domain of APP, hyperinsulinemia, and increased AA brain levels with an inverse correlation with IDE activity among homozygous, heterozygous, and wild-type mice for the insulysin gene trap model (7Y9). The IDE gene, located in chromosome 10q23.3, has been linked to type 2 diabetes (17, 18) and is close to a region of linkage for lateonset AD, representing a positional and biologic candidate for late-onset AD susceptibility (19) . To date, no mutations have been found in the canonic isoform of IDE and the recent haplotype association studies have produced inconsistent results (20Y24). Despite these controversial genetic data, the biochemical and functional findings suggest that IDE may participate in the pathogenesis of sporadic late-onset AD (7, 9, 19, 25, 26) . The recent advances in our knowledge on AA degradation raise the possibility that brain proteases may be manipulated to promote AA clearance. To facilitate these efforts, several aspects related to endogenous IDE expression, subcellular localization, and activity need to be carefully addressed in animal models of AD. The specific aim of our work was to study the profile of endogenous IDE during the neurodegenerative process in transgenic mice (Tg2576) brains, which carry the human amyloid precursor protein gene with the BSwedish[ double mutation associated with familial AD (APPsw) and robustly recapitulate the neuropathology of AD (27) . Early and late, temporal, and spatial characteristics of IDE expression were studied in Tg2576 mice at 4.5, 11, and 16 months of age. We found that aged Tg2576 mice showed a 2-fold increment in IDE protein levels as compared with 11 month olds, whereas no differences were found in the amount of IDE transcripts in whole brain homogenates, suggesting that the regulation of IDE gene expression in aged mice may occur at the posttranscription level. Moreover, at this stage, IDE appeared surrounding amyloid deposits within glial fibrillar acidic protein (GFAP)-positive astrocytes, suggesting that IDE was focally expressed by cells involved in the inflammatory response. Results from our in vitro experiments fully support the hypothesis that IDE expression is mediated by an inflammatory process involving mitogen-activated protein kinase (MAPK) signaling. The finding that AA deposition in aged Tg2576 mice is related to IDE overexpression at late stages of the neuropathologic process in this animal model of AD raises the possibility of a new role of IDE independent of its proteolytic activity in the process of amyloid deposition in the brain.
MATERIALS AND METHODS

Animals
Hemizygous Tg2576 mice (27) and nontransgenic strain littermates (NTg) were maintained on a 12-hour light/dark cycle and standard diet. Animal care was in accordance with an approved protocol following the institutional guidelines at New York University School of Medicine. A total of 32 animals were divided into 6 experimental groups as follows (number of animals and mean age T standard error of mean in parentheses): group 1: Tg2576 (n = 6; 4.92 T 0.15 months); group 2: NTg (n = 6; 4.75 T 0.11 months); group 3: Tg2576 (n = 4; 11.75 T 0.48 months); group 4: NTg (n = 6; 10.75 T 0.40 months); group 5: Tg2576 (n = 5; 16.3 T 0.44 months); and group 6: NTg (n = 5; 15.8 T 0.2 months).
Tissue Preparation
Mice were anesthetized with sodium pentobarbital (150 mg/kg intraperitoneally), perfused transaortically with sodium phosphate buffer, pH 7.4, and the brains (free of cerebellum and medulla) processed as described previously (28) . The right hemisphere was fixed overnight by immersion in a periodateYlysineYparaformaldehyde solution, subsequently transferred to phosphate-buffered saline (PBS) containing 20% glycerol and 2% dimethyl sulfoxide (DMSO), and stored at 4-C until sectioned. The left hemisphere was snap-frozen in liquid nitrogen for protein and RNA extraction. As a result of limitations imposed by the limited number of Tg2576 animals and the amount of material required for various biochemical procedures, whole brain homogenates were prepared instead of homogenates from isolated cerebral cortex.
Antibodies
Rabbit polyclonal BC2 antiserum was generated against a glutathione S-transferase (GST) fusion protein containing the sequence 97Y273 of rat IDE as described previously (29) . Anti-GST polyclonal antibodies were affinity purified using glutathione-(oxidized)Yagarose beads (Sigma, St. Louis, MO). Anti-IDE monoclonal antibodies were obtained by immunization of Balb/c mice with fulllength recombinant IDE (rIDE) following standard protocols. Anti-rIDE clones 1C1 and 3A2 (isotype IgG1) that did not recognize GST-IDE97-273 by direct enzyme-linked immunosorbent assay (ELISA) were further characterized using GST fusion proteins spanning 3 different regions of IDE: R1, amino acids 42Y186; R3, 262Y530; and R4, 531Y998, respectively. To obtain greater amounts of antibodies, selected clones were propagated in vivo by the production of ascitic fluid and purified according to standard protocols. Monoclonal anti-> actin was from Sigma. Rabbit polyclonal antineuronal specific enolase (NSE) and anti-GFAP were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and DAKO (Glostrup, Denmark), respectively. Monoclonal anti-flotillin 1 was from BD Transduction Laboratories, Inc. (Mountain View, CA). Monoclonal antibody IgG1 anti-A lactamase was provided by Dr. J. Santos from the University of Buenos Aires. Polyclonals anti-p38, antiphosphorylated p38, anti-ERK2, and monoclonal antiphospho ERK1/2 (p-ERK1 p44/p-ERK2 p42) were from Santa Cruz Biotechnology. Biotinylated goat anti-mouse IgG was from Vector Laboratories (Burlingame, CA). Cy5-streptavidin and Cy3-goat anti-rabbit IgG were from Amersham Biosciences (Buckinghamshire, U.K.).
Chemicals
Protein inhibitors phenylmethyl sulfonyl fluoride (PMSF), pepstatin, leupeptin, EDTA, and aprotinin as well as MAPK inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4 bis[2-aminophenylthio]butadiene) were from Sigma. Protein G-Sepharose was from Amersham Biosciences.
Protein Extraction Protocols
Portions of 50 to 70 mg of each frozen hemibrain were homogenized with a manual Teflon glass homogenizer in 1 mL of ice-cold PBS containing 1 mM PMSF, 5 Kg/mL pepstatin A, 5 Kg/mL leupeptin, and 5 Kg/mL aprotinin. The homogenates were centrifuged at 100,000 Â g at 4-C for 1 hour using a Beckman ultracentrifuge and a 50Ti rotor (Beckman, Palo Alto, CA). Supernatants corresponding to water-soluble brain fractions were aliquoted and stored at j80-C. Pellets were exhaustively washed in 0.5 M Na 2 CO 3 pH 11 to disrupt weak proteinYprotein associations and subjected to protein extraction using 2% sodium dodecyl sulfate (SDS) by homogenization and posterior centrifugation at 100,000 Â g at 4-C for 1 hour. SDS-soluble fractions were aliquoted and stored as described. Individual samples from each extraction step were grouped by transgene status and age. Six different poolsVfrom each extraction protocolVcorresponding to Tg2576 and control littermates were analyzed to assess IDE levels and activity. These were normalized by protein content as determined with a bicinchoninic acid assay (Pierce, Rockford, IL).
Immunoblotting
For Western blotting, aliquots of 10 to 50 Kg of proteins were subjected to electrophoresis on 7.5% SDSTris-Tricine polyacrylamide minigels and transferred to polyvinylidene fluoride (PVDF) membranes (Amersham Biosciences). After blocking overnight with 5% nonfat dry milkYPBS, membranes were probed with the primary antibodies in PBS containing 0.1% Tween 20 followed by horseradish peroxidaseYconjugated antigammaglobulin (Amersham Biosciences). For visualization, blots were incubated with ECL Plus (Amersham Biosciences), scanned in a STORM 840, and processed using the computer software ImageQuant (Amersham Biosciences).
Insulin-Degrading Enzyme and AA Quantitation by Enzyme-Linked Immunosorbent Assay AA40 and AA42 levels were assessed using a sandwich ELISA system commercially available (Signet Labs, Dedham, MA) and results expressed as ng/mg of tissue protein. IDE was quantified by a sandwich ELISA using monoclonal antibodies 3A2 and biotinylated 1C1 as previously described (30) . Levels of endogenous IDE were expressed as ng/mg of tissue protein. Determinations were performed in duplicate samples in 2 independent experiments for AA and in 4 independent experiments for IDE, respectively.
Insulin-Degrading Enzyme Immunoprecipitation and Activity Assay
To assess the activity of endogenous IDE, we followed a previously described protocol (30) with slight modifications as follows. Two hundred fifty micrograms of proteins from a PBS high-speed supernatant from brain homogenates was diluted in 500 KL of PBS, pH 7.5, containing 2 mM PMSF, 2 Kg/mL leupeptin, 2 Kg/mL aprotinin, and 2 Kg/mL pepstatin A and incubated with 9 Kg of each anti-IDE monoclonal antibodies 1C1 and 3A2 or anti->-actin monoclonal antibody as control, respectively, and protein G-Sepharose for 3 hours at room temperature. Immunocomplexes were washed 3 times in ice-cold PBS containing 0.4 M NaCl and 3 times in 0.1 M phosphate, pH 7 (degradation buffer) without protein inhibitors. The protein G-Sepharose beads were then incubated in 50 KL of degradation buffer containing 50,000 cpm of 125 Iinsulin (specific activity, 300 KCi/Kg; provided by Edgardo Poskus, University of Buenos Aires) for the indicated times at 37-C with constant agitation in the presence or absence of the following protease inhibitors: 5 mM EDTA, 1 mM 1,10-phenanthroline, 2 mM PMSF, 2 Kg/mL leupeptin, 2 Kg/mL pepstatin A, and 2 Kg/mL aprotinin. After incubation, Sepharose beads were centrifuged at 1,500 Â g for 5 minutes. Twenty microliters of the supernatant were removed, mixed with an equal volume of 8% SDS sample buffer, boiled, and resolved by 15% Tris-Tricine SDS-PAGE under nonreducing 
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¶, and CT, 5 ¶-gCATTTACCAgCggAgAACACACC-3 ¶; 573C, 5 ¶-TCgAATTCgACAgCGTTCACCTC-3 ¶ were used to amplify fragments called NT (102 bp) and CT (141 bp), respectively, from pCDNA3-IDE containing the coding region of rat IDE cDNA. After NT-CT ligation and subcloning into pGEM-T Easy vector (Promega. Madison, WI), a fragment of 259 bp was obtained. Competitor RNA was prepared using the RT-PCR Competitor Construction Kit (Ambion, Austin, TX) and quantified following the manufacturer_s instructions. Both cDNA from endogenous mRNA and competitor RNA were prepared by reverse transcription of 0.5 Kg of tissue RNA in the presence of a known amount of competitor RNA following standard protocols. Final PCR products were separated on 8.4% polyacrylamide gels, stained with ethidium bromide solution, visualized under an ultraviolet transilluminator (UVP Life Sciences, Cambridge, U.K.), and bands of 285 bp and 259 bp were quantified using Media Cybernetics Gel-Pro Analyzer software (version 3.1; Silver Spring, MD). The ratio of products obtained from the endogenous and exogenous targets at the end of the amplification reflects the initial ratio of endogenous target to the competitor. Three independent experiments were performed and results were expressed as copies of competitor mRNA/Kg of sample mRNA.
Immunohistochemistry
Serial coronal 40-Km free-floating sections were stored in sucroseYethylenglycolYPBS solution at j20-C until assayed. Retrieval of antigen sites, blocking of endogenous peroxidase activity, and blocking of nonspecific binding sites was performed according to standard protocols. A mouse-onmouse immunodetection kit from Vector Laboratories (Burlingame, CA) was used for immunolocalization of IDE with purified monoclonal antibodies 1C1/3A2 at 0.5 Kg/KL. Nonspecific immunohistochemical controls for anti-IDE included the omission of the primary antibody, the incubation of an adjacent section with 1 Kg/KL of 1C1/3A2 in the presence of 5 Kg/KL of rIDE, or with an unrelated antibodypurified mouse IgG1 monoclonal antibody anti-B. licheniformis exo small A-lactamase (31). Immunoreactivity was developed using 3,3-diaminobenzidine tetrahydrochloride (DAB) substrate with nickel ammonium sulfate intensification (Vector Laboratories). To visualize fibrillar AA deposits, sections were stained with 1% Thioflavine-S (Sigma) for 10 minutes and examined with a fluorescence microscopy as described subsequently. Double immunostaining of IDE and fibrillar deposits was assessed using 1C1/3A2 and thioflavin-S. For localization of IDE in activated astrocytes, we used a mix of 1C1/3A2 and anti-GFAP as primary antibodies. Specific immunoreactivity was visualized in a confocal microscopy (as described subsequently) with biotinylated goat anti-mouse IgG conjugated to Cy5-streptoavidin (blue fluorescence for IDE detected using helio/neon 633-nm laser) and Cy3-labeled goat anti-rabbit IgG (red fluorescence for GFAP detected using helio/neon 543-nm laser). To colocalize IDE in microglial cells, 1C1/3A2 immunoreactivity was detected as described previously and sections were further incubated with fluorescein isothiocyanate (FITC)-Lycopersicum esculentum (tomato) lectin (Sigma) overnight at 4-C and viewed under an argon 488-nm laser. Analysis of the images was performed as described subsequently.
Astrocyte Cultures and Treatments
Primary astrocytes were obtained from the cerebral cortex of 1-to 2-day-old neonatal Sprague-Dawley rats freed of meninges following protocols previously described (32) and kept in culture until confluency by addition of culture medium containing DMEM and Ham's F12 (1:1 v/v), 5 Kg/mL streptomycin, 5 U/mL penicillin, and supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA). For immunocytochemistry, cells were detached with 0.25% trypsin and plated at 0.5 to 1.5 Â 10 5 cells/well onto 8-well Lab-TeK chamber slide (Nunc, Naperville, IL). To obtain fibrillar AA, synthetic AA1-40 peptide (Bachem, Torrance, CA) was dissolved in DMSO to 250 KM, stored at -20-C for at least 4 weeks, and diluted to 5 KM in cell culture media just before use. After this procedure, AA solution contained predominantly fibrils when characterized by electron microscopy. Disaggregated (referred to as soluble) peptide was obtained by dissolving lyophilized peptide in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) and following the protocol as previously described (33) . Because fibrillar AA mediates inflammation by MAPK cascades, we tested its capability to induce astroglial IDE expression through ERK1/2 phosphorylation. Specificity of the effect was confirmed by inhibition of ERK1/2 with 50 KM of U0126. Stimulation with fibrillar AA was performed in 2 sets of plates containing cells cultured in serum-free media for 24 hours in the presence or absence of MAPK inhibitor (added 1 hour before stimulation). After 1 hour, one set was processed to test the levels of p-ERK1/2 (peak of kinase activation) and the other one was incubated overnight to quantify IDE expression. For immunolocalization of IDE, cells were fixed with p-formaldehyde, permeabilized with 0.1% Triton X-100, and blocked with 5% normal goat serum as previously described (30) . Slides were probed overnight at 4-C with 1C1/3A2 at 0.5 Kg/KL in blocking solution, incubated with Cy2-labeled goat antimouse (Amersham Biosciences) for 2 hours at room temperature in blocking buffer, extensively washed, coverslipped with mounting medium (Vector Laboratories), and viewed under a fluorescence microscope (Olympus BX50). Image analysis was performed as described subsequently. For the detection and relative quantification of ERK2, Phospho-ERK1/2, actin, and IDE by Western blot astrocytes were plated onto 24-wells plates at density of 8 Â 10 5 cells/well and treated as described previously. After treatment, medium was removed and stored for cytokines quantification using commercially available kits (BD optEIA; Pharmingen, San Diego, CA) and cells lysed in 100 KL of Laemmli sample buffer and aliquots (previously normalized by protein content) processed for immunoblots as previously described.
Image and Statistical Analysis
Immunostained brain sections were imaged with a digital Olympus BX50 microscope, and assessment of levels of AA burden and IDE/GFAP immunoreactivity was performed using the Image-Pro Plus software (Media Cybernetics). Additional analysis of double-labeled sections was performed by laser scanning confocal microscopy imaging sections on LSM5 Pascal microscope using a 3-frame filter and Zeiss LSM5 image examiner. For each case, a total of 6 brain sections (10 images per section) were analyzed to estimate the average number of immunolabeled cells per unit area (millimeters squared) and the average intensity of immunostaining (corrected optical density). To quantify the intensity of the fluorescence (corrected optical density) per unit area (millimeters squared) after AA treatments, images of at least 100 immunocytochemically stained cells were analyzed by Image-Pro Plus software (Media Cybernetics). Quantitative data were analyzed by one-way analysis of variance with a post hoc Tukey test or 2-tailed Student t-test to compare NTg and Tg2576 mice or AA treated and untreated cells were performed using GraphPad Prism 3.0 software. All results were represented as means T standard error of mean. p values lower than 0.05 were considered statistically significant.
RESULTS
Insulin-Degrading Enzyme Is Overexpressed in Aged Tg2576 Brains in Synchrony With AA Accumulation
To determine whether APPsw overexpression and sustained AA overproduction affect the regulation of endogenous IDE levels in vivo and if these parameters are modulated by aging, we examined brain tissue from Tg2576 mice and NTg littermates aged 4.5 months to 16 months. Toward this aim, specific anti-IDE monoclonal antibodies 1C1 and 3A2 were generated against a rIDE. Both monoclonal antibodies recognized linear epitopes within positions 262 to 530 of rat IDE sequence. Moreover, 1C1 and 3A2 were able to detect endogenous IDE by Western blot and specifically immunoprecipitated a full-length 115 kDa IDE from mouse brain that was recognized by polyclonal BC2 (not shown). As previously described, these antibodies were used to develop a sandwich ELISA assay using recombinant rat IDE (rIDE) as a standard (30) . IDE protein levels detected by ELISA in water-soluble brain fractions from all experimental groups analyzed is depicted in Figure 1A . In Tg2576 mice (closed squares), there were no substantial changes in protein IDE levels up to 11 months. However, a significant 2-fold increase (*, p G 0.05) was observed at 16 months as compared with 11-month-old animals (612 T 54.3 ng/mg vs 291.96 T 23.7 ng/mg, respectively). IDE amounts in 16-month-old Tg2576 animals were statistically different from all control samples analyzed (*, p G 0.05). No differences in IDE levels were observed among mice from the NTg groups (closed triangles), suggesting that steady-state levels of the IDE protein are not significantly modulated by aging in these animals. We next tested AA40 and AA42 in PBS and SDS-soluble brain fractions, respectively. As previously reported (34), as Tg2576 animals age, AA40 and AA42 (not shown) accumulate progressively with the former reaching the highest levels at 16 months of age. AA40 was more abundant than AA42 and both species were highly enriched in the SDS preparations as compared with water-soluble homogenates (not shown). Notably, the sharp increase in the amount of IDE (closed squares) in 16-month-old Tg2576 mice correlated with the exponential rise of SDS-soluble AA40 accumulation (opened circles) (Fig. 1B) . To confirm that the increase in IDE levels observed by ELISA in 16-month-old Tg2576 animals was the result of the full-length protease and not proteolytic fragments, we performed Western blots of water-soluble and SDS-soluble brain homogenates from all the mice involved in the study. The polyclonal antibody BC2 revealed that 115 kDa IDE was significantly increased in the brain of 16-as compared with 11-month-old Tg2576 mice (Fig. 1C) , whereas no differences were observed among NTg animals (not shown). When normalized to corresponding neuronal specific enolase (NSE) immunoreactivity, watersoluble IDE levels of Tg2576 mice at 16 months of age were on average almost 3-fold higher as compared with 1-monthold Tg2576 mice (0.715 T 0.115 arbitrary units [AU] vs 0.255 T 0.025 AU, **, p G 0.01) (Fig. 1C) . These results were fully consistent with the ELISA data and confirmed that IDE is increased at the time when brain AA species approached their highest levels. Subcellular localization experiments have shown that IDE is mainly located in the cytosol; however, it is also present in membrane fractions that may be more relevant to AA degradation (14, 34Y36). Therefore, we were interested in determining the levels of IDE present in water-insoluble compartments. The pellets obtained in PBS were exhaustively washed in carbonate buffer pH 11 to eliminate weak associations with integral membrane proteins and further treated with 2% SDS. For loading controls and normalization, membranes were reprobed with antibodies antiflotillin, a raft-associated protein (37) . In agreement with the results obtained with the water-soluble fractions, a significant 2-fold increment of IDE in SDS-soluble fraction from 16-month-old as compared with 11-month-old animals was found (2.495 T 0.22 vs 1.03 T 0.129, **, p G 0.01) (Fig. 1C) . 
Insulin-Degrading Enzyme Activity in Brain Homogenates From Young and Aged Tg2576 Mice
To evaluate if the higher levels of IDE detected in aged mice were reflected in its proteolytic activity, we used a test based on the immunoprecipitation of PBS-soluble proteins from mouse brain homogenates with both anti-IDE monoclonal antibodies (1C1 and 3A2) using 125 I-insulin as a substrate as previously described (30) . A representative SDS-PAGE and PhosphorImager analysis of 125 I-insulin degradation by Tg2576 and NTg animals of 11 and 16 months, respectively, and rIDE is shown in Figure 2 . Degraded fractions of 30.3 T 7.8% and 56.2 T 16.1% of 125 I-insulin by Tg2576 of 11 and 16 months, respectively, were observed as compared with the 100% defined for rIDEpositive control. Moreover, no differences in proteolytic activity were observed between 11-and 16-month-old NTg mice (degraded fractions of 27.6 T 2.23% and 26.8 T 2.2% of 125 I-insulin, respectively). Our results showed a 1.8-fold increase in the mean value of the enzyme activity in aged as compared with younger Tg2576 mice, which positively correlated with the 2-fold increase in the amount of IDE protein level. It is important to notice that these values did not reach statistical significance as a result of large standard errors of the mean, and therefore we cannot rule out that part of the total amount of immunoprecipitated IDE in aged Tg2576 mice may be inactive.
The Amount of Insulin-Degrading Enzyme mRNA Is the Same in Brain Homogenates From Young and Aged Tg2576 Mice
To evaluate if the increment of IDE observed in aged Tg2576 animals was associated with transcriptional upregulation of IDE mRNA, competitive RT-PCR was performed in brain tissue from 11 and 16 months animals normalized by GPDH (Fig. 3A) . Representative gels with the calibration curve performed with competitor mRNA to determine the levels of endogenous IDE mRNA from 11 and 16 months samples are shown in Figure 3B (left panel). No significant differences were detected in the amount of IDE transcripts in whole brain homogenates from 11-and 16-month-old Tg2576 mice (Fig. 3B, right panel) as well as compared with 16-month-old NTg mice (not shown). Our results indicate that IDE increment detected in aged Tg2576 mice was not the result of a widespread increase in its mRNA levels and suggest that regulation of IDE in aged mice may occur at the posttranscriptional level. Alternatively, a localized overexpression may not be reflected in total brain mRNA.
The Intensity of Astroglial Activation Correlates With Insulin-Degrading Enzyme Overexpression in Tg2576Mice
To test whether late inflammatory foci would be accompanied by IDE expression, quantitative Western blotting and immunohistochemistry of the astrocytic-specific marker GFAP were performed. There was a sharp increase in GFAP levels from brain homogenates at 16-month-old as compared with 11-month-old Tg2576 (3.66 T 0.15 AU and 1.63 T 0.05 AU, respectively) (*, p G 0.05), which correlated with the upregulation of the p-ERK1/2 kinase (3.29 T 0.12 AU and 1.93 T 0.092 AU, respectively) (*, p G 0.05) and a widespread activation of astrocytes associated to deposited AA in the hippocampus, brain cortices (visual, auditory, entorhinal, and piriform), and amygdaloid nuclei of the affected brain (Fig. 4) . In our study, plaques were detected at 11 months of age in agreement with the quantitative ELISA data of AA levels. Although a cytoplasmic label homogenously distributed along neurons from all regions of the brain was seen, IDE overexpression (black) was related to cells in the vicinity of plaques in 11- (Fig. 5A ) and 16-month-old Tg2576 mice as well as in the outer rim of the thioflavin-S positive deposits (yellow) (Fig. 5B) . This localized IDE staining was not found in NTg mice of all ages analyzed, although a cytoplasmic neuronal staining similar to Tg2576 mice was detected (not shown). To further explore whether IDE immunoreactivity surrounding AA plaques overlapped with glial cells, labeling with anti-GFAP (red, astrocytes) or FITC-tomato lectin (green, microglia) and 1C1/3A2 (purple, anti-IDE) was performed. We observed that 15 T 7% and 61 T 10% of GFAP-immunoreactive astrocytes in the vicinity of plaques were strongly positive for IDE (purple) in 11-and 16-month-old Tg2576 mice, respectively (Fig. 5CYE ), in accordance with the increments observed by ELISA and Western blot. By contrast, well-defined fluorescent (green) microglial cell bodies surrounding amyloid plaques (Fig. 5F ) lacked IDE immunoreactivity (Fig. 5G) . Merging of both images (Fig. 5H) ruled out microglialYIDE overproduction and suggests that the rim of IDE staining at the plaque periphery (Fig. 5B ) may be the result of dystrophic neurites (38, 39) .
Fibrillar AA Induces Insulin-Degrading Enzyme Upregulation in Astrocyte Through the Activation of Mitogen-Activated Protein Kinase Cascade
To explore a potential mechanism by which IDE is upregulated surrounding plaques in aged Tg2576 mice, we conducted in vitro experiments in primary astrocytes cultures exposed to 5 KM soluble or fibrillar AA (sequences 1Y40) (Fig. 6A) . A significant 1.75-fold increment was observed by Western blot in IDE after treatment with fibrillar peptide as compared with control cultures (treated with 5% DMSO) (30.4 T 3.75 AU vs 17.3 T 2.04 AU, *, p G 0.05), and no differences were detected when soluble AA was used (20.37 T 2.57 vs 25.14 T 2.02 AU) (Fig. 6B ). These data were further supported by immunocytochemistry results that showed that fibrillar AA exposure increased the intensity of cytoplasmic and membrane-associated IDE staining per cell in primary rat astrocytes approximately 40% relative to controls (mean fluorescence [optical density]/mean area [mm 3 ] = 0.07 AU vs 0.11 AU) (Fig. 6C) . At this concentration, no cell loss was detected as measured by a nuclear stain, DAPI (not shown).
Taking into account that AA specifically promotes phosphorylation and nuclear translocation of ERK1/2 (40) in cultured rat cortical astrocytes, we decided to explore the involvement of this signaling pathway on IDE expression. Specific inhibition of the ERK1/2 pathway was confirmed by the strong decrease in the levels of p-ERK1/2 after the addition of U0126 (2.3-fold reduction as compared with control) as assessed by Western blot without alteration on ERK2 and actin levels (Fig. 7A ). Under these experimental conditions, the observed stimulation of IDE expression after fibrillar AA exposure was approximately 30% as compared with DMSO or reverse peptide AA (sequences 40Y1)-treated cells. Overexpression of IDE by fibrillar AA was reverted by U0126 (Fig. 7B) confirming the involvement of ERK1/2 cascade on IDE expression.
DISCUSSION
The mechanisms by which IDE mRNA and protein steady-state levels are regulated in the brain are poorly understood. In this study, we used both in vivo and in vitro strategies to explore the association between IDE levels and AA accumulation. We found that IDE, a key protease involved in the clearance of AA from the brain, is overexpressed in an active form by glial cells in aged Tg2576 mice (16 months). It was previously reported that the AA burden in these mice increases over their lifespan (16Y17 months) and the plaque generation time in this animal model has been estimated to be approximately 1 year. Moreover, aging is not associated in Tg2576 with an increase of A-secretase activity (41) , and the augmented production of AA is not sufficient to induce amyloid deposition at early ages. The positive correlation between measurements of IDE protein and its activity suggests that the increased IDE levels in aged Tg2576 were not a compensation for reduced activity of the enzyme and support the notion that in this animal model, IDE activity is unaffected by aging. Our finding of similar IDE levels in NTg and Tg2576 mice up to 11 months is in agreement with a recent report in which IDE was detected by Western blot in 5-and 14-month-old NTg and Tg2576 brain homogenates using BC2 anti-IDE polyclonal antibody (42) . By contrast, reduction in IDE expression in aged mice was reported using different anti-IDE polyclonal antibodies and different animal models of AD (43, 44) . The variability in the pattern of expression and activity of endogenous IDE from various transgenic mice models of AD may be the consequence of differences in their genetic backgrounds and/ or in the specificity of anti-IDE antibodies used.
Competitive RT-PCR did not show significant differences between the amounts of IDE transcripts in whole brain homogenates from 11-and 16-month-old animals despite the protein increment observed, suggesting that during this temporal window, the global rate of IDE transcription does not change. These data are in agreement with the reported changes of Neprilysin mRNA expression in this animal model (45) . The lack of a positive correlation between the total IDE mRNA and protein raises the possibility that IDE is regulated at a posttranscriptional level, including increased stability of mRNA or decreased protein turnover rate resulting from age-related modifications. The former possibility could be experimentally addressed by in vitro experiments exposing cell cultures to TGF-A 1 , a known inductor of APP mRNA stabilization (46) . Regarding posttranslational modifications, IDE may be oxidized in the hippocampus of AD brains and this change may render IDE less effective in degrading AA (43) . Our sandwich ELISA and the immunoprecipitation activity assay are based on monoclonal antibodies that do not recognize posttranslational modifications. Therefore, we were likely detecting total soluble IDE and cannot rule out that a fraction of IDE may be oxidized and inactive in Tg2576 mice. This is the first report to our knowledge that shows IDE immunoreactivity in Tg2576 brain sections. We demonstrated that in old Tg2576 mice, IDE was distributed along a concentric ring next to dystrophic neurites and in activated astrocytes, suggesting that chronic AA deposition in Tg2576 mouse brain may induce a selective IDE overexpression by astrocytes. The highly localized IDE immunoreactivity pattern that we found may also explain the discrepancy between whole brain mRNA and IDE protein levels detected. These immunohistochemical data are consistent with the strong increase in GFAP levels observed by Western blot in 16-month-old Tg2576 mice and are in accordance with a previous report indicating that AA deposits may induce local astrocyte activation together with upregulation of Neprilysin (45) . IDE overexpression associated with AA deposition in Tg2576 may be highly sensitive to pathologic changes in the environment of glial cells. It was previously reported (47) that the recruitment of glial cells in Tg2576 mice is a rather slow process. In our study, the presence of IDE in reactive astrocytes and surrounding amyloid deposits at 16 months of age was always associated with the confluence of small amyloid cores, reinforcing that the accumulation of IDE depends on plaque age rather than on the sole presence or size of fibrillar amyloid cores. The lack of IDE overexpression by microglial cells may be explained by the different responses of each cell type for each chemokine produced in different phases during acute or chronic inflammation as recently proposed (48) . In this regard, protein kinase C (PKC), mainly involved in MAPK/ERK cascade, was reported to be less expressed in microglia as compared with astrocytes, suggesting that different patterns of expression of PKC in the 2 cell types (49) contribute to the differences in the ability of specific stimuli to enhance responses in astrocytes but not in microglia. At the present stage of our investigation, however, we can only speculate whether the low percentage of GFAP-immunoreactive astrocytes positive for IDE observed in young Tg2576 brain indicates the lack at this age of the specific stimuli or an inhibition of astroglial IDE expression. Noteworthy, enzymatically active IDE accumulation in Tg2576 mice brain does not correlate with the observations by our group and others that were obtained from cortex and hippocampus of patients with AD and in cortical microvessels with amyloid angiopathy (25, 26, 30) . Notably, amyloid cores from Tg2576 mice lacked IDE immunoreactivity opposite to a previous report showing colocalization of IDE with amyloid deposits in AD brain (50) but in accordance with a comprehensive proteomic analysis of senile plaques from postmortem AD brain tissues (51) . Our results are in agreement with the notion that the profile of inflammatory markers between Tg2576 and human AD brains is different (52) , reflecting differences in inflammatory responses triggered by fibrillar AA between human and rodents. In this sense, plaque formation in Tg2576 mice may be less influenced by AA posttranslational modifications as a result of their shorter generation time as compared with human AD (53) . In addition, AA levels in Tg2576 mice are relatively much higher than in sporadic AD, and they appear to be sufficient to initiate seed formation and plaque growth without additional factors that may be critical in sporadic AD related to APOE genotype, cholesterol levels, inflammation, and age-related oxidative damage, which may in turn influence IDE regulation.
Our in vitro experiments indicate that fibrillar AA, a potent activator of glial cells, promotes IDE expression in astrocytes through ERK 1/2 phosphorylation, reinforcing the notion that IDE may be directly involved in brain inflammatory pathways. It was previously reported that neuronal IDE is a downstream target in the insulin receptor signaling cascade mediated by phosphatidylinositol-3 kinase (PI3K)-Akt phosphorylation (54) and that this pathway is inhibited in primary neuronal cultures by extracellular fibrillar AA (55) or by intraneuronal aggregates of AA (56) . Contradictory experimental evidence involves AA in the activation of MAPK cascades, including JNK (57), ERK1/2 (58), and p38 (59) . The inhibition of IDE overexpression by fibrillar AA on U0126-pretreated primary cortical astrocytes suggests that fibrillar AA triggers different signaling cascades that target IDE expression. Moreover, IDE overexpression resulting from ERK1/2 activation by fibrillar AA in vivo and in vitro may explain the reduction of diffuse AA loads in Tg2576 mice (60) . The lack of detection of p-p38 by fibrillar AA (not shown) in primary rat astrocytes is in agreement with a previous report, suggesting that this kinase is not functional in cultured rat cortical astrocytes (40) . Remarkably, after AA treatment, levels of IL-1A and IL-6 in the supernatant were undetectable (not shown), probably as a result of the low sensitivity of the capture ELISA assay used or a lack of response of primary rodent astrocytes to secrete these inflammatory cytokines after AA stimulation. Our results suggest that ERK1/2 is an upstream signaling pathway contributing to IDE upregulation by fibrillar AA in astrocytes pointing to a causal relationship between an inflammatory cascade and IDE expression. Notably, the pattern of IDE expression that we report at different ages in Tg2576 is in agreement with the profile of IL-1A, TGF-A, IL-6, and IL-10-positive astrocytes (61) and advanced glycation end products (AGEs) immunoreactivity (62), previously described. The novo synthesis inside activated glial cells from aged Tg2576 mice of IL-6, IL-10, and AGEs was proposed by different authors as a protective mechanism developed during lifespan in this animal model of AD. In this context, because IDE is unable to degrade aggregated amyloid peptides (29) , a sustained overexpression of IDE by astrocytes in Tg2576 at late stages of neuropathologic alterations may be interpreted as part of a late reaction triggered by fibrillar AA toward degrading soluble AA peptides to limit plaque growth and its associated disruption of synaptic circuits (63) . Alternatively, it may be a defensive strategy aimed to protect neurons from death by functions still unexplored for IDE such as the inhibition of apoptosis or promotion of cell survivalVhypotheses that could be experimentally tested.
